Related Experiment Videos
Interstitial brachytherapy for malignant brain tumors: preliminary results
M Bernstein1, N Laperriere, P Leung
1Division of Neurosurgery, Toronto Western Hospital, Ontario, Canada.
Neurosurgery
|March 1, 1990
Summary
Interstitial brachytherapy using iodine-125 shows promise for select patients with recurrent malignant astrocytoma and brain metastasis. While not conclusive for initial therapy, it offers survival benefits in specific recurrent cases.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Oncology
Background:
- Malignant brain tumors present significant treatment challenges.
- Interstitial brachytherapy offers a localized treatment approach.
Purpose of the Study:
- To evaluate the experience with interstitial brachytherapy in patients with malignant brain tumors.
- To assess outcomes for newly diagnosed and recurrent malignant astrocytoma, and recurrent cerebral metastasis.
Main Methods:
- High-activity iodine-125 sources were temporarily implanted using a stereotactic technique.
- Patients were divided into groups for newly diagnosed malignant astrocytoma, recurrent malignant astrocytoma, and recurrent metastasis.
Main Results:
- Median survival was 60 weeks for newly diagnosed malignant astrocytoma and 44 weeks for recurrent malignant astrocytoma.
- Two of three patients with recurrent metastasis survived over 40 weeks post-implant.
- Complications occurred in 21.7% of patients, with 26.1% requiring a second operation.
Conclusions:
- Interstitial brachytherapy is beneficial for selected patients with recurrent malignant astrocytoma.
- The technique may offer survival advantages for patients with solitary recurrent cerebral metastasis.